Hillsdale Investment Management Inc. Invests $2.01 Million in Bioventus Inc. $BVS

Hillsdale Investment Management Inc. bought a new position in Bioventus Inc. (NASDAQ:BVS) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 269,909 shares of the company’s stock, valued at approximately $2,008,000.

Several other large investors have also recently made changes to their positions in the company. Nantahala Capital Management LLC increased its holdings in shares of Bioventus by 10.0% in the third quarter. Nantahala Capital Management LLC now owns 5,810,662 shares of the company’s stock worth $38,873,000 after purchasing an additional 529,820 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Bioventus by 4.4% in the third quarter. Vanguard Group Inc. now owns 2,924,788 shares of the company’s stock worth $19,567,000 after purchasing an additional 122,749 shares during the last quarter. Royce & Associates LP increased its holdings in shares of Bioventus by 15.6% in the third quarter. Royce & Associates LP now owns 1,262,976 shares of the company’s stock worth $8,449,000 after purchasing an additional 170,900 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Bioventus by 1.8% in the fourth quarter. Geode Capital Management LLC now owns 1,120,238 shares of the company’s stock worth $8,337,000 after purchasing an additional 19,388 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Bioventus by 10.7% in the third quarter. Dimensional Fund Advisors LP now owns 743,431 shares of the company’s stock worth $4,973,000 after purchasing an additional 71,624 shares during the last quarter. 62.94% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on BVS shares. Cantor Fitzgerald raised Bioventus to a “strong-buy” rating in a report on Wednesday, March 4th. Barrington Research reissued an “outperform” rating and set a $14.00 price objective on shares of Bioventus in a research note on Friday, May 22nd. CJS Securities started coverage on Bioventus in a research note on Friday, March 27th. They set a “market outperform” rating and a $14.00 price objective on the stock. Finally, Craig Hallum boosted their price objective on Bioventus from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $14.00.

Insider Activity at Bioventus

In other news, Director Michelle Mcmurry-Heath sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $8.79, for a total transaction of $105,480.00. Following the transaction, the director owned 44,997 shares of the company’s stock, valued at approximately $395,523.63. This represents a 21.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 33.00% of the company’s stock.

Bioventus Stock Performance

Shares of NASDAQ BVS opened at $8.51 on Monday. The business’s 50 day moving average is $9.67 and its two-hundred day moving average is $8.54. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.69 and a quick ratio of 1.13. Bioventus Inc. has a 1-year low of $5.81 and a 1-year high of $11.25. The stock has a market capitalization of $710.93 million, a P/E ratio of 20.76, a PEG ratio of 1.10 and a beta of 0.67.

Bioventus (NASDAQ:BVS) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.06. The company had revenue of $132.09 million for the quarter. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. As a group, research analysts expect that Bioventus Inc. will post 0.77 EPS for the current year.

Bioventus Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.